factory cardiac output could not be achieved and attempts at resuscitation were abandoned one hour after cardiopulmonary bypass had been discontinued. Cardiac transplantation with a human donor was performed in December 1967 by Barnard, 3 and this heralded a virtual epidemic of cardiac transplants throughout the world, with 100 being performed during the next 12 months by 64 teams in 22 countries. Not surprisingly, the results were poor, and after two years clinical cardiac transplantation fell into disrepute, as many began to appreciate the magnitude of the problems of rejection and infection associated with this procedure.
Although successful experimental cardiac transplantation was first achieved at Stanford University in 1959, an active research programme was continued until clinical transplantation was introduced in January 1968 with the knowledge and skill gained by a decade of experiment. The number -of cardiac transplants performed at Stanford has steadily increased to roughly 25 a year. Maintaining a concurrent, aggressive research programme has allowed continuing improvements in postoperative management to be made, so that the expected oneyear survival rate is 700'. This success rate is comparable or superior to those reported for renal transplantation from unrelated donors.
We review briefly the experience in the first 150 Immunological monitoring is carried out by measuring circulating T ("killer") lymphocytes by the spontaneous rosette-formation test with sheep erythrocytes. This test, however, is most useful during the first 30 days, after which there is an increase in false-positive results. The dosage and frequency of ATG administration are guided by measuring the half life of circulating rabbit globulin and the rosette test. The primary goal in the first 30 days after transplantation is to depress the number of T cells (as measured by the rosette test) to less than 10°" of normal. A rise in the rosette fraction is seen one to three days before rejection is confirmed by biopsy.
Acute rejection episodes confirmed histologically are treated with increased immunosuppression. "Pulses" of methylprednisolone (one gram intravenously daily for three days) are administered as well as small doses of actinomycin D. A short course of ATG is begun again. Heparin is given to avoid possible vascular damage by fibrin and platelets. Of rejection episodes treated in this way, 950,, can be reversed. Late postoperative rejection episodes are less severe and frequent. They are usually treated by increasing the dose of oral prednisone.
LATE MANAGEMENT
Patients are seen in the outpatient clinic twice weekly for two months, weekly for two months, then monthly if still resident in the area. Chest x-ray examination, electrocardiography, and appropriate laboratory investigations are performed at these times. Once a year patients are readmitted for coronary arteriography, left ventriculography, and cardiac biopsy. Patients are maintained on a low cholesterol, low sodium diet. Antiplatelet agents are used to control the development and progression of the atheroma-like condition that develops after most organ grafts. (The development of ischaemia in the cardiac graft is painless since the heart is denervated.) Rejection episodes diagnosed electrocardiographically and by cardiac biopsy are treated aggressively.
Retransplantation has been used to treat both advanced atherosclerosis in the graft and intractable acute rejection. In these cases it is the only alternative to certain death and seven patients have undergone a second transplantation (three successfully).
Results
The figure shows the survival rate in the 150 transplant recipients, together with the survival rate of patients who were accepted as recipients, but died before a suitable donor was found. survival rate has improved from 22%o in 1968 to 680o in 1977. Survival rates of patients who underwent transplantation in the last five years have improved (figure). Apart from increased experience, the enhanced survival correlates with several distinct improvements in management that have been developed or tested in the laboratory before clinical use. The endomyocardial bioptome provides histological evidence of rejection and allows myocardial histology to be correlated with drug treatment. The use of antithymocyte globulin produced in rabbits was started in October 1973 and has been used in the last 86 patients. Since the introduction of rabbit ATG, measurement of the half life of circulating rabbit globulin has been used to modulate immunosuppressive treatment in individual patients, and, as described above, early activation of the immune response has been detected by measuring circulating T lymphocyte concentrations.
Since 1970 an acute awareness of graft atherosclerosis has prompted the treatment of all patients with dipyridamole and warfarin, and this regimen, together with the reduction of plasma lipid concentrations associated with a low-fat diet, may be responsible for the observed reduction of graft atherosclerosis as measured by yearly coronary arteriograms. Two patients with advanced immune-mediated athersclerosis, however, needed to undergo a second transplantation.
The complications of generalised immunosuppression are the major factors accounting for morbidity and mortality after cardiac transplantation. Infection is the most serious complication, though osteoporosis, aseptic necrosis of the joints, and change in appearance may affect rehabilitation. Infection caused 45 deaths (3000 of all patients), the lungs being the most common site. Out of 319 infectious episodes, 150 (470,) were pulmonary, 35 (11 0) septicaemic, 22 (7%O) occurred in the urinary tract, and 10 (300) in the central nervous system. Infection is more common after cardiac transplantation than renal transplantation because more intense immunosuppression is needed to maintain cardiac function during rejection. The care of cardiac transplant recipients is thus dissimilar to that of recipients of hepatic and renal grafts because of the narrower margin between maintaining effective organ function and death, and at Stanford the care of transplant recipients is solely in the hands of the cardiac surgeon until the patient is discharged. Rejection accounted for 19 deaths (13"0 of all patients).
Discussion
For the patient in end-stage cardiac failure that is unresponsive to maximal medical and surgical treatment there is a choice between cardiac transplantation and death. For patients who fulfil the criteria for suitable cardiac recipients the one-year survival rate is close to 700. In 900) of long-term survivors in our series physical activity has returned to normal and most have resumed active employment.
There are few published data on the cost of cardiac transplantation. In the United States the cost of transplantation has been estimated at roughly $40 000 for the transplant year and $2500 yearly thereafter. The cost to society of an occupationally incapacitated person would be $32 000 in support money and loss of occupational contributions. Thus expenditure on cardiac transplantation would roughly equal the cost of medical treatment for end-stage cardiac disease, even if only 300 of transplant recipients were rehabilitated.7 Naturally, an economic value cannot be placed on life or rehabilitation for the person or family concerned.
Factors that contribute to the relative success of transplantation at Stanford are a concomitant research programme that has led to the development and the continued refinement of various aspects of patient care and management of rejection, the total commitment of a section of the cardiovascular surgery team and research workers to the transplant programme, and an increased awareness of the unique problems associated with cardiac transplantation that derives from 10 years of experience in this field.
Other centres that have the appropriate facilities for cardiac transplantation and suitably trained staff should perhaps reconsider cardiac transplantation as an alternative to death in certain patients. GPs have had notice from the DHSS that the ten-dose container of oral polio vaccine may lose its potency after it has been opened. Is it reasonable to give polio at the same time as smallpox to people going abroad, and to store the smallpox in the freezer part and the oral polio in the main part of the refrigerator, and to throw both smallpox and polio phials away at the same time ? (The smallpox usually lasts 14 days.)
The DHSS official advice is that live viral vaccines should not be administered at the same time but that a three-week interval should be allowed between them. The American practice, however, is to give several live viral vaccines at the same time as it is felt in that country that there is no risk in so doing. As many travellers rarely leave themselves sufficient time for proper protection and polio is quite common among recent arrivals, in cases of urgency I think your questioner's procedure a reasonable one. With regard to storage of the oral polio once it has been opened, the DHSS advise that it should be thrown away immediately, and this should be adhered to as any infection introduced into the container would destroy its potency. If the smallpox vaccine distributed in the plastic tubing by the Lister Institute is stored in the freezer compartment of the refrigerator at about -10°C the potency is assured for one year.
Should a 16-year-old girl have her tonsils removed after five attacks of tonsillitis in five months ?
